샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777784

세계의 항생제 내성 진단 시장

Antimicrobial Resistance Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 281 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항생제 내성 진단 세계 시장은 2030년까지 61억 달러에 이를 전망

2024년에 45억 달러로 추정되는 항생제 내성 진단 세계 시장은 분석 기간인 2024-2030년 CAGR 5.3%로 성장하여 2030년에는 61억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 PCR 기술은 CAGR6.5%를 나타내고, 분석 기간 종료시에는 17억 달러에 이를 것으로 예측됩니다. 면역분석법 기술 분야의 성장률은 분석 기간중 CAGR 5.6%로 추정됩니다.

미국 시장은 12억 달러로 추정, 중국은 CAGR 8.5%로 성장 예측

미국의 항생제 내성 진단 시장은 2024년에 12억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 12억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.5%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.5%와 5.2%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.4%를 나타낼 전망입니다.

세계의 항생제 내성 진단 시장 - 주요 동향과 촉진요인 정리

항균제 내성(AMR) 진단제가 전 세계적으로 주목받는 이유는?항균제 내성(AMR)이 심각하게 증가함에 따라 진단약은 약제 내성 감염의 위협에 대응하기 위한 중요한 도구로 자리매김하고 있습니다. 박테리아, 바이러스, 곰팡이, 기생충이 표준 치료에 대한 내성을 획득함에 따라, 내성 균주를 신속하고 정확하게 검출하는 능력은 효과적인 환자 관리에 매우 중요합니다. 병원 내 감염(HAI)과 다제내성(MDR) 병원균 증가로 신속하고 정확한 AMR 진단약의 도입이 요구되고 있습니다. 공중보건기관이 조기 발견의 필요성을 강조하는 가운데, 정부와 민간 의료 기관은 AMR 진단 기술에 많은 투자를 하고 있습니다. 이러한 발전은 부적절한 항생제 사용을 줄이고 환자 맞춤형 치료를 통해 궁극적으로 내성균의 확산을 완화하는 데 필수적입니다.

기술 혁신은 어떻게 진단 정확도를 높이고 있는가?최근 분자진단학, AI를 활용한 분석 도구, 차세대 염기서열분석기(NGS)의 발전으로 AMR 검출의 속도와 정확도가 크게 향상되고 있습니다. PCR 기반 분석과 전장 유전체 시퀀싱을 통해 의료진은 내성 유전자를 놀라운 정확도로 식별할 수 있게 되었습니다. 또한, 바이오센서, 마이크로플루이딕스 장치, 현장 검사(POCT) 키트는 현장에서 신속한 검사를 가능하게 하여 AMR 진단에 혁명을 일으키고 있습니다. 이러한 개발로 임상의는 배양 기반 검사 결과를 기다릴 필요 없이 데이터에 기반한 치료 방침을 결정할 수 있게 되었습니다. 또한, 머신러닝 알고리즘을 진단 플랫폼에 통합하여 병원체 식별 및 내성 프로파일링을 효율화하여 진단 시간을 단축하고 있습니다.

AMR 진단 시장에 존재하는 과제와 기회는 무엇인가?AMR 진단약의 중요한 역할에도 불구하고, 높은 비용, 규제적 장애물, 저자원 환경에서의 접근성 제한 등의 문제가 보급의 걸림돌로 작용하고 있습니다. 특히 개발도상국의 많은 의료시설에서는 첨단 진단 솔루션을 도입하는 데 필요한 인프라가 제대로 갖추어져 있지 않습니다. 그러나 시장 기회는 자원이 부족한 지역을 위해 설계된 저렴하고 사용하기 쉬운 진단 기술의 확대에 있습니다. 민관 파트너십과 자금 지원 이니셔티브는 비용 효율적인 진단 플랫폼 연구를 촉진하고 보다 광범위한 접근성을 보장하기 위해 노력하고 있습니다. 또한, WHO와 CDC의 AMR 감시 및 진단을 촉진하는 세계 이니셔티브는 더 높은 인식과 정책 주도형 시장 성장을 가속하고 있습니다.

AMR 진단 시장의 주요 성장 촉진요인은?항균제 내성 진단제 시장의 성장은 약제 내성 감염의 부담 증가, 신속 진단 기술에 대한 투자 증가, AMR 대응 프로그램에 대한 규제 당국의 지원 확대 등 여러 요인에 의해 이루어질 것으로 보입니다. 개인 맞춤형 의료와 정밀 진단의 출현은 혁신적인 AMR 검출 도구에 대한 수요를 가속화하고 있습니다. 또한, 정부 주도의 항균제 스튜어드십 프로그램의 확대로 임상 워크플로우에 신속 진단 검사의 통합이 촉진되고 있습니다. AI를 활용한 진단 솔루션의 채택이 증가하고 있으며, 생명공학 기업과 의료기관의 협업이 시장 확대를 더욱 촉진하고 있습니다. 또한, 질병의 조기 발견을 통한 헬스케어 비용 절감을 위한 전 세계적인 추진은 AMR 진단약에 대한 투자를 확대하여 이 분야의 지속 가능한 성장에 힘을 실어주고 있습니다.

부문

기술(PCR 기술, 면역측정 기술, 미생물 배양 기술, NGS 기술, 신속 및 POC(Point of Care) 진단 기술, 기타 기술), 최종사용자(병원 최종사용자, 진단실험실 최종사용자, 제약 기업 및 바이오테크놀러지 기업 최종사용자, 기타 최종사용자)

조사 대상 기업 예

  • Abbott Laboratories, Inc.
  • Accelerate Diagnostics, Inc.
  • Acurx Pharmaceuticals, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Innoviva Inc
  • Nabriva Therapeutics US, Inc.
  • Paratek Pharmaceuticals, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.06

Global Antimicrobial Resistance Diagnostics Market to Reach US$6.1 Billion by 2030

The global market for Antimicrobial Resistance Diagnostics estimated at US$4.5 Billion in the year 2024, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. PCR Technology, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Immunoassay Technology segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 8.5% CAGR

The Antimicrobial Resistance Diagnostics market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Antimicrobial Resistance Diagnostics Market - Key Trends & Drivers Summarized

Why Is Antimicrobial Resistance (AMR) Diagnostics Gaining Global Attention? The alarming rise of antimicrobial resistance (AMR) has positioned diagnostics as a critical tool in combating the threat of drug-resistant infections. As bacteria, viruses, fungi, and parasites develop resistance to standard treatments, the ability to quickly and accurately detect resistant strains is crucial for effective patient management. The increasing prevalence of hospital-acquired infections (HAIs) and multidrug-resistant (MDR) pathogens has necessitated the adoption of rapid and precise AMR diagnostics. With public health organizations stressing the need for early detection, governments and private healthcare entities are investing heavily in AMR diagnostic technologies. These advancements are vital in reducing inappropriate antibiotic use and tailoring patient-specific treatments, ultimately mitigating the spread of resistance.

How Are Technological Innovations Enhancing Diagnostic Accuracy? Recent advancements in molecular diagnostics, AI-powered analytical tools, and next-generation sequencing (NGS) are significantly improving the speed and precision of AMR detection. PCR-based assays and whole-genome sequencing are enabling healthcare providers to identify resistance genes with remarkable accuracy. Furthermore, biosensors, microfluidic devices, and point-of-care testing (POCT) kits are revolutionizing AMR diagnostics by facilitating rapid on-site testing. These developments allow clinicians to make data-driven treatment decisions without waiting for prolonged culture-based test results. The integration of machine learning algorithms into diagnostic platforms is also streamlining pathogen identification and resistance profiling, enhancing efficiency and reducing diagnostic turnaround time.

What Challenges and Opportunities Exist in the AMR Diagnostics Market? Despite the critical role of AMR diagnostics, challenges such as high costs, regulatory hurdles, and limited accessibility in low-resource settings hinder widespread adoption. Many healthcare facilities, especially in developing nations, lack the necessary infrastructure to implement advanced diagnostic solutions. However, market opportunities lie in the expansion of affordable, easy-to-use diagnostic technologies designed for resource-limited regions. Public-private partnerships and funding initiatives are driving research into cost-effective diagnostic platforms, ensuring wider accessibility. Additionally, global initiatives by WHO and CDC promoting AMR surveillance and diagnostics are fostering greater awareness and policy-driven market growth.

What Are the Key Growth Drivers of the AMR Diagnostics Market? The growth in the antimicrobial resistance diagnostics market is driven by several factors, including the rising burden of drug-resistant infections, increased investment in rapid diagnostic technologies, and growing regulatory support for AMR control programs. The emergence of personalized medicine and precision diagnostics is accelerating demand for innovative AMR detection tools. Additionally, the expansion of government-led antimicrobial stewardship programs is encouraging the integration of rapid diagnostic testing into clinical workflows. The rising adoption of AI-driven diagnostic solutions, along with collaborations between biotech firms and healthcare institutions, is further propelling market expansion. Moreover, the global push for reducing healthcare costs through early disease detection is amplifying investments in AMR diagnostics, positioning this sector for sustained growth.

SCOPE OF STUDY:

The report analyzes the Antimicrobial Resistance Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid and Point-of-Care Diagnostics Technology, Other Technologies); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Pharma and Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Abbott Laboratories, Inc.
  • Accelerate Diagnostics, Inc.
  • Acurx Pharmaceuticals, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Innoviva Inc
  • Nabriva Therapeutics US, Inc.
  • Paratek Pharmaceuticals, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Antimicrobial Resistance Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Need for Rapid Diagnostic Solutions Amid Increasing AMR Cases
    • Growing Investments in AI-Powered Pathogen Detection Technologies
    • Advancements in Molecular Diagnostics Enhancing AMR Detection Accuracy
    • Increasing Adoption of Point-of-Care AMR Testing Solutions
    • Surging Demand for Genomic & Next-Generation Sequencing in AMR Diagnostics
    • Expansion of Portable & Handheld AMR Diagnostic Devices for Remote Testing
    • Growing Integration of Smart Sensors & Digital Health Platforms in AMR Testing
    • Increasing Focus on Personalized Treatment Strategies Using AMR Diagnostics
    • Government & Public Health Initiatives Supporting Early AMR Detection
    • Collaboration Between Diagnostic Companies & Pharmaceutical Firms to Combat AMR
    • Rising Awareness & Adoption of AMR Diagnostic Kits in Veterinary Medicine
    • Evolving Laboratory Automation Trends Driving Efficiency in AMR Detection
    • Emergence of Cost-Effective AMR Diagnostic Solutions for Low-Resource Settings
    • Growing Reimbursement Support & Insurance Coverage for AMR Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antimicrobial Resistance Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for PCR Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for PCR Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for PCR Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Immunoassay Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Microbiology Culture Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Microbiology Culture Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Microbiology Culture Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for NGS Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for NGS Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for NGS Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Rapid & Point-of-Care Diagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Rapid & Point-of-Care Diagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Rapid & Point-of-Care Diagnostics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Spain 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Russia 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Australia 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: India 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: South Korea 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Argentina 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Brazil 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Mexico 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Iran 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Israel 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: UAE 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Africa 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제